Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis
Christopher D. Wiley, Alexis N. Brumwell, Sonnet S. Davis, Julia R. Jackson, Alexis Valdovinos, Cheresa Calhoun, Fatouma Alimirah, Carlos A. Castellanos, Richard Ruan, Ying Wei, Harold A. Chapman, Arvind Ramanathan, Judith Campisi, Claude Jourdan Le Saux
Christopher D. Wiley, Alexis N. Brumwell, Sonnet S. Davis, Julia R. Jackson, Alexis Valdovinos, Cheresa Calhoun, Fatouma Alimirah, Carlos A. Castellanos, Richard Ruan, Ying Wei, Harold A. Chapman, Arvind Ramanathan, Judith Campisi, Claude Jourdan Le Saux
View: Text | PDF
Research Article Cell biology Pulmonology

Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis

  • Text
  • PDF
Abstract

Accumulation of senescent cells is associated with the progression of pulmonary fibrosis, but mechanisms accounting for this linkage are not well understood. To explore this issue, we investigated whether a class of biologically active profibrotic lipids, the leukotrienes (LT), is part of the senescence-associated secretory phenotype. The analysis of conditioned medium (CM), lipid extracts, and gene expression of LT biosynthesis enzymes revealed that senescent cells secreted LT, regardless of the origin of the cells or the modality of senescence induction. The synthesis of LT was biphasic and followed by antifibrotic prostaglandin (PG) secretion. The LT-rich CM of senescent lung fibroblasts (IMR-90) induced profibrotic signaling in naive fibroblasts, which were abrogated by inhibitors of ALOX5, the principal enzyme in LT biosynthesis. The bleomycin-induced expression of genes encoding LT and PG synthases, level of cysteinyl LT in the bronchoalveolar lavage, and overall fibrosis were reduced upon senescent cell removal either in a genetic mouse model or after senolytic treatment. Quantification of ALOX5+ cells in lung explants obtained from idiopathic pulmonary fibrosis (IPF) patients indicated that half of these cells were also senescent (p16Ink4a+). Unlike human fibroblasts from unused donor lungs made senescent by irradiation, senescent IPF fibroblasts secreted LTs but failed to synthesize PGs. This study demonstrates for the first time to our knowledge that senescent cells secrete functional LTs, significantly contributing to the LT pool known to cause or exacerbate IPF.

Authors

Christopher D. Wiley, Alexis N. Brumwell, Sonnet S. Davis, Julia R. Jackson, Alexis Valdovinos, Cheresa Calhoun, Fatouma Alimirah, Carlos A. Castellanos, Richard Ruan, Ying Wei, Harold A. Chapman, Arvind Ramanathan, Judith Campisi, Claude Jourdan Le Saux

×

Figure 6

Senescence-associated leukotriene synthesis promotes pulmonary fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
Senescence-associated leukotriene synthesis promotes pulmonary fibrosis....
WT C57BL/6J mice received a single intratracheal injection of PBS (vehicle control) or bleomycin (Bleo, 1.9 U/kg). Mice received, from days 7–14,vehicle (Veh) or 50 mg/kg/day ABT-263 by gavage. (A) Level of p16INK4a and p21WAF1 mRNA levels normalized to tubulin mRNA. (B) Activation of cytosolic phospholipase A2 (cPLA2) was determined by calculating the ratio of the level of expression of phosphorylated cPLA2 to the level of expression of total cPLA2. Representative pictures of Western blot of lung lysates collected day 14 after the bleomycin injury for the expression of the phosphorylated form of cPLA2, cPLA2-S505P, and nonphosphorylated form cPLA2. n = 3 lysates per group. (C) Level of expression of mRNA of gene encoding enzymes of the leukotriene (ALOX5 and LTC4S) and the prostaglandins (PTGDS, PTGS2, and PTGES) biosynthesis pathways was measured by qPCR normalized to tubulin mRNA, in samples collected 14 days after bleomycin injury. Data are presented as dot plot graphs or heatmap. (D) Lipids were extracted from broncho-alveolar lavage fluid (BALF) collected 14 days after bleomycin injury and treatment with vehicle or ABT-263. BALF lipid content was analyzed for cysteinyl leukotrienes and for PGE2 by ELISA. (E) Representative pictures of Picrosirius red staining of lungs collected 21 days after bleomycin injury and treatment with vehicle or ABT-263. Original magnification, ×100. (F) Hydroxyproline levels obtained using the right lung lobes of mice, 21 days after bleomycin injury and treatment with vehicle or ABT-263. Unless stated otherwise, lung and BALF from at least 5 PBS-treated mice, 5 bleomycin + vehicle-treated mice, and 3 bleomycin + ABT-263 mice were analyzed. Statistical analyses were performed using 1-way ANOVA test. *P ≤ 0.05; **P ≤ 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts